Jonathan Grant

Photo of Jonathan Grant
Honorary Senior Research Fellow, RAND Europe
Off Site Office


Ph.D., Faculty of Medicine, King's College London

Media Resources

This researcher is available for interviews.

To arrange an interview, contact the RAND Europe Media Relations at +44 (1223) 273-898, or email

More Experts


Jonathan Grant is Honorary Senior Research Fellow at RAND Europe and director of the King's Policy Institute at King's College London. His main research interests are on health R&D policy, the use of research and evidence in policy making, and population policy issues. He and colleagues continue to provide analytical support on the implementation of the English Department of Health internationally acclaimed R&D strategy, Best Research for Best Health. In 2011 Grant led a rapid review of the Greek R&D system for the Minister of Education (2011) and was co-principal investigator of the influential report, Medical Research, What's it worth, that estimated the economic returns from biomedical and health research in the UK (2008). Grant was president of RAND Europe between June 2006 and October 2012. Grant oversaw the doubling of RAND Europe's activity in Europe, the founding of a vibrant and successful office in Brussels, and the establishment of the Cambridge Centre for Health Services Research, a joint venture with the University of Cambridge. Grant joined RAND in 2002. He was formerly Head of Policy at The Wellcome Trust. He received his Ph.D from the Faculty of Medicine, University of London, and his B.Sc. (Econ) from the London School of Economics.

Research Focus

Concurrent Non-RAND Positions

Director of the King's Policy Institute, King's College London

Recent Projects

  • Review of future options for science and technology policy for an incoming UK government

Recent Media Appearances

Interviews: BBC; The Guardian; The Independent; The Times


  • American pharmacist with senior woman in pharmacy

    The Most Dangerous Mistake You Can Make During Flu Season

    Despite public awareness campaigns in the United States and Europe, many people persist in the mistaken belief that antibacterial drugs — like amoxicillin and azithromycin — are the best treatment for flu. And many doctors simply surrender when patients demand them, ignoring the scientific and medical truth: when treating the flu, antibacterial drugs just don't work.

    Oct 28, 2013 | Reuters

  • viruses and bacteria under a microscope

    Who Killed Mrs X? The Global Threat of Antimicrobial Resistance

    Antimicrobial drugs are no longer working as they once did. The bugs that they are supposed to attack are becoming increasingly resistant. Microbes follow the same rules of evolution as we do. Through reproduction and natural selection the fittest survive.

    Sep 18, 2013 | The RAND Blog

  • euro in lightbulb

    Innovating Out of a Crisis: How Research and Innovation Are Key to Europe's Future

    Are research and innovation the way out of Europe's current woes? And is the way to administer and fund research and innovation working? Jonathan Grant and Rebecca Schindler suggest more could be done.

    Mar 13, 2013 |

  • Research Funding and Economic Growth

    Publicly funded R&D investment is a coherent policy to support long term economic growth. Our only note of caution is about how far and how fast that growth can be delivered because the evidence we have is out of date and skewed towards the experience of just one country, write Jonathan Grant and Jon Sussex.

    Nov 29, 2011 | Research Fortnight

  • It's 2018, and the Economy's Hot...

    If the nation is to emerge from a recession in a position of strength, we should chart our course carefully now. The government bailout of the banking sector could yield a substantial payout one day - and now is the time to earmark that money for our knowledge sector, writes Jonathan Grant.

    Oct 22, 2008 | Research Fortnight

  • Consequences of a Graying World

    Consequences of a Graying World, in Christian Science Monitor.

    Jun 29, 2007 | Christian Science Monitor